TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15001599
Drug: Pioglitazone (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (45 mg daily)
Study: 9232133
Drug: Remifentanil, 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil, 1 microgram/kg, given over 30 s followed by a continuous infusion of 0.1 microgram.kg‐1.min‐1
Study: 9232133
Drug: Remifentanil+midazolam, 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil+midazolam, 0.5 microgram/kg, given over 30 s followed by a continuous infusion of 0.05 microgram.kg‐1.min‐1
Study: 16154442
Drug: 24-hour continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-hour continuous intralipid infusion (20%, 0.4 mg mL(‐1) h(‐1))
Study: 10895854
Drug: Pinitol 20
Normalized name: FOMITOPSIS PINICOLA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pinitol 20 mg x kg(‐1) x day(‐1) (n = 12)
Study: 1622179
Drug: Fleroxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fleroxacin (400 mg every 24 h)
Study: 1622179
Drug: Ciprofloxacin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (500 mg every 12 h)
Study: 30600794
Drug: Meaning and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meaning and Purpose (MaP) therapy
Study: 29129894
Drug: Combination package
Normalized name: COMBINATION PACKAGE (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination package containing a personalized daughter-directed reminder leaflet and an additional informational leaflet for the mother requesting her recommendation for screening.
Study: 22330025
Drug: Whole-body vibration
Normalized name: Insects (whole body), mite dermatophagoides farinae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-body vibration therapy (9-15 min, frequency = 20-30 Hz, amplitude = 0.44-0.60 mm)
Study: 28065165
Drug: Whole-body vibration
Normalized name: Insects (whole body), mite dermatophagoides farinae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-body vibration therapy
Study: 19265567
Drug: Compulsory community
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compulsory community treatment orders
Study: 15376806
Drug: Teaching predictive
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teaching predictive values of features (central or peripheral) for biological properties of animals
Study: 11400949
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone propionate, 880 microg every 12 hours for 12 weeks from the start date of their CPB conditioning regimen.
Study: 9744697
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg sublingual glyceryl trinitrate (GTN)
Study: 18722631
Drug: All Tadalafil
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All Tadalafil doses
Study: 15778231
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment plus stabilising exercises
Study: 12870339
Drug: Hunan aqueous
Normalized name: ethylcellulose aqueous dispersion type A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hunan aqueous drainage (HAD) implantation with mitomycin C (MMC) (0.4 mg/ml, 1 to 5 mins)
Study: 8757659
Drug: Manually selected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manually selected tube potentials with a molybdenum/molybdenum target filter combination
Study: 7129748
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine infusions over a two-year period
Study: 7129748
Drug: Single-blind placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-blind placebo infusion
Study: 7129748
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine infusions
Study: 28942805
Drug: Dialectical Behavior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialectical Behavior Therapy for Children (DBT-C)
Study: 15834219
Drug: Low-dose alcoholic
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose alcoholic beverage (0.4 g/kg)
Study: 15834219
Drug: High-dose alcoholic
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose alcoholic beverage (0.8 g/kg)
Study: 1791932
Drug: Alcohol (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (both doses)
Study: 1907056
Drug: Diltiazem (90-360
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (90-360 mg per day based on body weight)
Study: 6322505
Drug: Ketoconazole 400
Normalized name: ketoconazole 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole 400 mg/day for 3 days
Study: 3709030
Drug: Ketoconazole 200
Normalized name: ketoconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole 200 mg/day for 6 days
Study: 6322505
Drug: Miconazole 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miconazole 100 mg/day for 14 days
Study: 31604631
Drug: Dosing cups
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosing cups
Study: 31604631
Drug: Oral syringes
Normalized name: Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral syringes
Study: 28274772
Drug: Ibuprofen 400
Normalized name: ibuprofen 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 400 mg three times daily for 5 days
Study: 24284414
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily mesalazine
Study: 24284414
Drug: Three times
Normalized name: WELLBUTRIN 100 MG Oral Tablet, Three Times Daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three times daily mesalazine
Study: 22682806
Drug: Gemcitabine (Gem)
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine (Gem) treatment arm with CA 19-9 <90 U/mL
Study: 22682806
Drug: Gemcitabine (Gem)
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine (Gem) treatment arm with CA 19-9 ≥90 U/mL
Study: 22682806
Drug: Gemcitabine (Gem)
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine (Gem) treatment arm with RT quality assurance per protocol and CA 19-9 <90 U/mL
Study: 22682806
Drug: CA 19-9
Normalized name: CA-19-9 antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: CA 19-9 serum level ≥90 U/mL
Study: 19125777
Drug: Glimepiride (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride (titrated up to 6 mg/day, mean dose 4.5 mg/day)
Study: 17381394
Drug: Ertapenem (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ertapenem (1 g qd)
Study: 17381394
Drug: Piperacillin/tazobactam (3.375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin/tazobactam (3.375 g q6h)
Study: 10402160
Drug: Thrice‐weekly buprenorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice‐weekly buprenorphine dose schedules (64, 84, and 112 mg weekly)
Study: 10402160
Drug: Daily buprenorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily buprenorphine dose of 16 mg/70 kg
Study: 10402160
Drug: Thrice‐weekly buprenorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice‐weekly buprenorphine dose schedules
Study: 12265803
Drug: ML Cu
Normalized name: SYRINGE 10-12ML CURVED TIP
Approvals — FDA: no, EMA: no, PMDA: no
Description: ML Cu 250-standard
Study: 12265803
Drug: ML Cu
Normalized name: SYRINGE 10-12ML CURVED TIP
Approvals — FDA: no, EMA: no, PMDA: no
Description: ML Cu 250-short
Study: 27783532
Drug: Sildenafil thermosensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil thermosensitive vaginal gel
Study: 21251653
Drug: LMWH (enoxaparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: LMWH (enoxaparin 40 mg, once daily) plus LDA
Study: 21251653
Drug: UFH (5000
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFH (5000 units, twice daily) plus LDA
Study: 10749603
Drug: Intraperitoneal 5-fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal 5-fluorouracil (5-FU) administered at 0.6 g/m2/day for 6 days (day 4 to day 10) plus intravenous 5-FU (1 g) during surgery
Study: 10749603
Drug: Intraperitoneal 5-FU
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intraperitoneal 5-FU (full treatment)
Study: 1525128
Drug: 60% phosphoric
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60% phosphoric acid gel with 0.5% NaF (Orthoprep) for 5 seconds
Study: 1525128
Drug: 37% non‐fluoridated
Approvals — FDA: no, EMA: no, PMDA: no
Description: 37% non‐fluoridated phosphoric acid gel (Coe) for 60 seconds
Study: 29431455
Drug: 90-minute Prolonged
Normalized name: TAGETES MINUTA FLOWER OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90-minute Prolonged Exposure therapy sessions
Study: 29431455
Drug: 60-minute Prolonged
Normalized name: TAGETES MINUTA FLOWER OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60-minute Prolonged Exposure therapy sessions
Study: 25858265
Drug: Disease activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disease activity guided dose reduction of adalimumab or etanercept
Study: 23298304
Drug: Transanal, submucosal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transanal, submucosal injection of 4 x 1 mL of dextranomer in hyaluronic acid
Study: 15134793
Drug: Activities of
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activities of Daily Living (ADL) skills training
Study: 9215249
Drug: Cetirizine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine (20 mg/day)
Study: 31339474
Drug: CKD (eGFR
Approvals — FDA: no, EMA: no, PMDA: no
Description: CKD (eGFR < 60 mL/min/1.73 m2)
Study: 28775001
Drug: Intranasal theophylline
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal theophylline
Study: 26036454
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy (8-week randomized controlled trial)
Study: 22104038
Drug: Cytisine (25-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytisine (25-day course of tablets)
Study: 22104038
Drug: Nicotine Replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine Replacement Therapy (NRT) (usual care: eight weeks of NRT patch and/or gum or lozenge)
Study: 14551293
Drug: Aggressive cytoreduction
Normalized name: ZO SKIN HEALTH Aggressive Anti-Aging Program KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive cytoreduction with hyperthermic intraperitoneal chemotherapy (HIPEC) followed by systemic chemotherapy (fluorouracil‐leucovorin)
Study: 14551293
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment consisting of systemic chemotherapy (fluorouracil‐leucovorin) with or without palliative surgery
Study: 7601919
Drug: Subgingival application
Normalized name: DOXYCYCLINE 10% SA SUBGINGIVAL SUSP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subgingival application of 2% minocycline ointment administered at baseline, week 2, and months 1, 3, 6, and 9.
Study: 7601919
Drug: Systemic administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic administration of minocycline following scaling/root planing for 10 days.
Study: 7601919
Drug: Both subgingival
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both subgingival and systemic administration groups.
Study: 30972456
Drug: Rabeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole (20 mg/day)
Study: 26523444
Drug: FOLFOX-A (oxaliplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX-A (oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, 5-fluorouracil 2400 mg/m2, nab-paclitaxel 150 mg/m2 every 2 weeks)
Study: 26523444
Drug: FOLFOX-A (oxaliplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX-A (oxaliplatin 65 mg/m2 if grade 2 neuropathy developed)
Study: 21857520
Drug: Hyperbaric articaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric articaine 84 mg (group A)
Study: 21857520
Drug: Hyperbaric bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric bupivacaine 7 mg along with fentanyl 10 μg (group B+F)
Study: 7646751
Drug: One-month intensive
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-month intensive training program in psychosocial medicine
Study: 23880099
Drug: Low-dose tranexamic
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose tranexamic acid (10 mg kg(‐1) followed by 1 mg kg(‐1) h(‐1) infusion and 1 mg kg(‐1) into the CPB)
Study: 23880099
Drug: High-dose tranexamic
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose tranexamic acid (30 mg kg(‐1) followed by 16 mg kg(‐1) h(‐1) infusion and 2 mg kg(‐1) into the CPB)
Study: 14687273
Drug: Combination (COMBO)
Normalized name: NexGard Combo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination (COMBO)
Study: 3926612
Drug: Nitroglycerin patches
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin patches delivering 5 mg/24 hours
Study: 3926612
Drug: Nitroglycerin patches
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin patches delivering 10 mg/24 hours
Study: 3926612
Drug: Nitroglycerin patches
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin patches delivering 20 mg/24 hours
Study: 3926612
Drug: Nitroglycerin patches
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin patches delivering 30 mg/24 hours
Study: 31988233
Drug: LEE011 (ribociclib)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LEE011 (ribociclib) 400 mg daily for 21 days
Study: 30485685
Drug: Parecoxib sodium
Normalized name: parecoxib sodium
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Parecoxib sodium administered 30 minutes before surgery.
Study: 30485685
Drug: Saline administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline administered 30 minutes before surgery (Control group).
Study: 23589163
Drug: PTH(1-84) (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTH(1-84) (100 μg/day) + ibandronate (150 mg/month)
Study: 15837454
Drug: Patient intervention
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient intervention (targeted communication about fall and fracture prevention and osteoporosis diagnosis and treatment delivered through mailings)
Study: 10486394
Drug: Phenytoin 300
Normalized name: phenytoin 300 mg oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenytoin 300 mg/day
Study: 10486394
Drug: Sodium Valproate
Normalized name: sodium valproate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium Valproate 1500 mg/day
Study: 1797358
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg metaraminol
Study: 1797358
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg metaraminol
Study: 1797358
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg metaraminol
Study: 1797358
Drug: Metaraminol (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metaraminol (all doses)
Study: 29231297
Drug: Warm needling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warm needling therapy applied to acupoints in the neck and lumbus (Fengchi (GB 20), Tianzhu (BL 10), Neck-Bailao (EX-HN 15), Wangu (GB 12), Tianyou (TE 16), Dachangshu (BL 25), Qihaishu (BL 24), Jiaji (EX-B 2) of L5). Treatment given once every two days, three times a week.
Study: 29231297
Drug: Warm needling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warm needling therapy applied only to acupoints in the neck (same as group A). Treatment given once every two days, three times a week.
Study: 18781850
Drug: Fluvastatin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin (80 mg/day, n = 420)
Study: 16373648
Drug: B vitamins
Normalized name: B-50 Hi Potency B Vitamins
Approvals — FDA: no, EMA: no, PMDA: no
Description: B vitamins (2 mg of folate, 25 mg of B6, and 400 microg of B12)
Study: 9048404
Drug: Enoxaparin 40
Normalized name: ENOXAPARIN 40MG/0.4ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 40 mg once daily for 1 month (30 +/‐ 4 days)
Study: 7849445
Drug: 900 mg
Normalized name: diosmin 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg aspirin daily
Study: 7849445
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg aspirin daily
Study: 3315266
Drug: Evening administration
Normalized name: Evenity
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Evening administration at 2000 hr
Study: 3315266
Drug: Evening administration
Normalized name: Evenity
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Evening administration at 2200 hr
Study: 30136619
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acid supplementation (5 capsules of fish-oil-derived omega-3, each 1 g containing 180 mg eicosapentaenoic acid and 120 mg docosahexanoic acid)
Study: 24774260
Drug: Optimized glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimized glucose control with insulin (target glucose, 80-120 mg/dL)
Study: 24774260
Drug: Conventional control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional control (target glucose, <180 mg/dL)
Study: 22660798
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) and TNF-α inhibitors
Study: 16470437
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (10 mg/kg before operation and twice thereafter at 8-hour intervals)
Study: 12433712
Drug: Highest quartile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highest quartile of insulin
Study: 10651393
Drug: Leflunomide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leflunomide (100 mg once daily for 3 days, then 20 mg once daily)
Study: 1759005
Drug: Salbutamol 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol 0.3 mg, tid + Beclomethasone dipropionate 0.2 mg, tid
Study: 1759005
Drug: Salbutamol 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol 0.3 mg, tid + Placebo
Study: 6130076
Drug: Methaqualone 300
Normalized name: methaqualone 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methaqualone 300 mg
Study: 31215299
Drug: Remote Ischemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remote Ischemic Conditioning (RIC) treatment (4 cycles of 5-minute ischemia followed by 5-minute reperfusion)
Study: 31215299
Drug: Sham-device treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham-device treatment
Study: 17511193
Drug: 0.05% betamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% betamethasone gel
Study: 25797743
Drug: Dabrafenib 150
Normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dabrafenib 150 mg po bid for 14 days
Study: 25797743
Drug: Dabrafenib plus
Normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dabrafenib plus trametinib 2 mg po daily for 14 days
Study: 25797743
Drug: Dabrafenib therapy
Normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dabrafenib therapy
Study: 25797743
Drug: Dabrafenib and
Normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dabrafenib and trametinib therapy
Study: 22490614
Drug: Chinese herbal
Normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herbal medicine formulae
Study: 22490614
Drug: Chinese herbal
Normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herbal medicine formulae (specifically Jing Fan Bai Du san)
Study: 20968018
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (photon therapy)
Study: 16043964
Drug: Oral ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ganciclovir (3 g/day)
Study: 16043964
Drug: Oral valacyclovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral valacyclovir (8 g/day)
Study: 12072104
Drug: HBV vaccination
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBV vaccination with levamisole (80 mg after each hemodialysis session for 4 months)
Study: 10084038
Drug: Periarticular injection
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Periarticular injection of 1.5 ml (40 mg/ml) methylprednisolone acetate and 1.5 ml (20 mg/ml) lignocaine (MP group)
Study: 10084038
Drug: Isotonic sodium
Normalized name: ISOTONIC SODIUM CHLORIDE SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic sodium chloride and 1.5 ml (20 mg/ml) lignocaine (non‐MP group)
Study: 2187525
Drug: Intravenous treosulfan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous treosulfan
Study: 2187525
Drug: Intravenous treosulfan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous treosulfan plus cisplatinum
Study: 6142462
Drug: Alprazolam (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (0.5 to 1 mg 3-times daily)
Study: 29083258
Drug: Dienogest 2
Normalized name: dienogest 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dienogest 2 mg once daily for 24 weeks
Study: 26791921
Drug: High-dose caffeine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose caffeine (loading 20 mg/kg and maintenance of 15 mg/(kg·d) after 24 h)
Study: 26791921
Drug: Low-dose caffeine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose caffeine (loading 20 mg/kg and maintenance of 5 mg/(kg·d) after 24 h)
Study: 24902983
Drug: USL255 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: USL255 (200 mg/day)
Study: 9973769
Drug: 2.0 g
Normalized name: Fifty50 2.0 Glucose Meter
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 g vitamin C
Study: 9973769
Drug: 105 g
Normalized name: soap/boric ac/sod lauryl sulf 105 gram TOPICAL CAKE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 105 g carbohydrate
Study: 8268118
Drug: Intravenous fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fentanyl (100 micrograms)
Study: 20719809
Drug: Vaginal micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal micronized progesterone (200 mg, 3 times a day)